Answers are grounded in this paper and cite their sources.
OPS-2071 is a novel quinolone antibacterial agent characterized by low oral absorption that reduces the risk of adverse events typical of fluoroquinolone class antibiotics. The in vitro and in vivo antibacterial activities of OPS-2071 against Clostridioides difficile were evaluated in comparison to vancomycin and fidaxomicin.
No takes yet. Share an insight, caveat, or question.
Oka et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: